Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
about
Characterizing the burden of premature ejaculation from a patient and partner perspective: a multi-country qualitative analysis.Interventions for guttate psoriasisSystemic pharmacological treatments for chronic plaque psoriasisAdverse effects of biologics: a network meta-analysis and Cochrane overviewPromising new treatments for psoriasisTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesKey design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an exampleOff-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyPutting together the psoriasis puzzle: an update on developing targeted therapiesTreatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumabIL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasisAnti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with PsoriasisDemyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review.Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis.Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.Biologic safety in psoriasis: review of long-term safety data.Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis.Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report.Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy.Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin.Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasisCurrent status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for PsoriasisThe 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACHComparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab.Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity.Use of biologic agents in combination with other therapies for the treatment of psoriasisBiologics in the management of psoriasis.Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.Update of the management of chronic psoriasis: new approaches and emerging treatment options.Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances.
P2860
Q21245614-26B7D267-75AF-44C0-9599-6D2E3F27F2DEQ24188296-C7A62AB4-C41C-45C0-B4A8-29DF3FAFD78DQ24188334-AC08BA7C-2BE4-4471-8238-79C22DEA45E1Q24234197-3E3D4CCA-9AD9-405C-B360-F2098BD5851BQ24598008-22E93B95-E0D4-47A9-A9FC-540E0793820BQ26764867-8A86A1AE-4A1A-4791-801F-26A60F139F46Q26766368-41CEB0C9-EAB7-4391-8560-BBEF375F5D12Q26827714-ECA24479-BC2E-4221-B160-3A4680E4AE7BQ27026785-27291F5C-6C00-4548-8B92-E745AEB0F04AQ28069819-F30F4463-24DB-434B-950B-EC876E8DBC4CQ28268370-ACD35B30-1AB0-4233-9C2A-68E70D65C79BQ28554923-E3559A39-8BA3-4068-B9D5-0F84E2D97A28Q30251926-7C6BAE90-3D99-4C47-BEEC-46A47F811487Q30412650-1C4EA599-2945-4D18-ACD3-C2699C06B3C0Q30542069-2626E6D6-5AFE-46EF-8E35-BDA72CF936DFQ30574065-0A03B760-40AF-4A46-AB02-E83624FE731AQ30904076-26649460-46A6-4DC4-A54D-FC04ABCE3223Q31137103-EEB0A6A9-0D73-4336-BAB1-36249FF7675FQ33386650-52CCBD92-CCC0-49F1-A647-6843251B0E8DQ33625546-058FEB90-8CED-48E7-B577-940AE6650E02Q33651502-DDCE376C-16AA-4FA7-99B7-8142CA7EE7F5Q33785083-51FF5D07-56BE-460D-B723-39D170CA101BQ33830208-FC902223-FD33-41CD-ABBA-4BC2C3222EBCQ33896449-A86D902E-008D-4E3F-A730-FE6102D0181DQ33939033-0DDE8476-53FB-4BF4-AA58-4061C9D76250Q33969217-F549169C-ED32-4779-A802-E0898084748DQ34041797-F84E85DA-3BC0-4D89-A7DC-2B2D3EB0B2D7Q34112840-DD71AC51-BC3A-48AF-83E7-5BB007D3D56EQ34166896-D1A7BEEE-C327-4DDD-A46D-CA9D9915475EQ34385556-8E6BCA19-9825-4FC3-B2BC-638A9F2015AAQ34393068-59612A23-3623-4C18-9322-3C3D0DF197D8Q34497018-B6552CF3-EB77-4A04-A4E5-A08E599B79ADQ34502118-79F5AFD3-4E98-46FF-BB61-97D7220DEE04Q34516612-AD180B0E-68B6-4334-8A9E-18CD62751A75Q34517278-7671457D-1BEE-4685-AE4B-7ACAA2A20B10Q34553755-51B7F214-AEB9-45C0-9DEB-8442F9EFC5FFQ34620257-4A14CD81-2EF9-4EFA-A0EA-1F4131C94F03Q34620323-D36F0302-DBFE-49C9-B221-FA3B1F98F9BDQ34620375-7E8A40F4-7C7A-4F43-A7BB-C79818046705Q34631384-5DF59D09-CC66-474C-9265-1C20B94C87E6
P2860
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Adalimumab therapy for moderat ...... d, controlled phase III trial.
@ast
Adalimumab therapy for moderat ...... d, controlled phase III trial.
@en
Adalimumab therapy for moderat ...... d, controlled phase III trial.
@nl
type
label
Adalimumab therapy for moderat ...... d, controlled phase III trial.
@ast
Adalimumab therapy for moderat ...... d, controlled phase III trial.
@en
Adalimumab therapy for moderat ...... d, controlled phase III trial.
@nl
prefLabel
Adalimumab therapy for moderat ...... d, controlled phase III trial.
@ast
Adalimumab therapy for moderat ...... d, controlled phase III trial.
@en
Adalimumab therapy for moderat ...... d, controlled phase III trial.
@nl
P2093
P1476
Adalimumab therapy for moderat ...... ed, controlled phase III trial
@en
P2093
Alan Menter
Bruce E Strober
Craig L Leonardi
Kenneth Gordon
Martin Kaul
Martin Okun
Richard G Langley
Stephen K Tyring
P304
P356
10.1016/J.JAAD.2007.09.010
P407
P577
2007-10-23T00:00:00Z